Literature DB >> 7082530

Assay and characterisation of debrisoquine 4-hydroxylase activity of microsomal fractions of human liver.

G C Kahn, A R Boobis, S Murray, M J Brodie, D S Davies.   

Abstract

1 A method for the assay of debrisoquine 4-hydroxylase activity in vitro by microsomal fractions of human liver is described. The assay utilises gas chromatography-mass spectrometry with d9-4-hydroxydebrisoquine as internal standard. 2 The limit of detection of 4-hydroxydebrisoquine was 2 ng ml -1 and the coefficient of variation was 4.4%. 3 Debrisoquine 4-hydroxylase activity was linear with protein to concentrations above 2.1 mg ml -1 and with incubation times of at least 15 min. 4 Debrisoquine 4-hydroxylase is a microsomal enzyme with a requirement for NADPH. Activity was inhibited by carbon monoxide. It is concluded that the activity is catalysed by cytochrome P-450. 5 In three samples of human liver the mean value for Vmax of debrisoquine 4-hydroxylase activity was 69.9 +/- 14.3 pmol mg -1 min -1 and for Km it was 130 +/- 24 microM. 6 The only variable from smoking status, alcohol ingestion, sex of the patients, source of liver sample and presence of liver disease that had a significant effect on 4-hydroxylation of debrisoquine was the presence of liver disease. This was associated with a decrease in enzyme activity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082530      PMCID: PMC1402066          DOI: 10.1111/j.1365-2125.1982.tb01430.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  26 in total

1.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

2.  The metabolism of debrisoquine in rat and man.

Authors:  M Angelo; L G Dring; R Lancaster; R L Smith
Journal:  Biochem Soc Trans       Date:  1976       Impact factor: 5.407

3.  Determination of debrisoquin and its 4-hydroxy metabolite in plasma by gas chromatography/mass spectrometry.

Authors:  S L Malcolm; T R Marten
Journal:  Anal Chem       Date:  1976-05       Impact factor: 6.986

4.  Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man.

Authors:  J G Allen; P B East; R J Francis; J L Haigh
Journal:  Drug Metab Dispos       Date:  1975 Sep-Oct       Impact factor: 3.922

5.  Genetic evidence for the involvement of different oxidative mechanisms in drug oxidation.

Authors:  L A Wakile; T P Sloan; J R Idle; R L Smith
Journal:  J Pharm Pharmacol       Date:  1979-05       Impact factor: 3.765

6.  Polymorphic hydroxylation of debrisoquine.

Authors:  G T Tucker; J H Silas; A O Iyun; M S Lennard; A J Smith
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

7.  The metabolism of [14C]-debrisoquine in man.

Authors:  J R Idle; A Mahgoub; M M Angelo; L G Dring; R Lancaster; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

8.  Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine.

Authors:  I Kitchen; J Tremblay; J André; L G Dring; J R Idle; R L Smith; R T Williams
Journal:  Xenobiotica       Date:  1979-07       Impact factor: 1.908

9.  Metabolism of debrisoquine sulphate in rat, dog and man.

Authors:  J G Allen; A N Brown; T R Marten
Journal:  Xenobiotica       Date:  1976-07       Impact factor: 1.908

10.  Polymorphic hydroxylation of Debrisoquine in man.

Authors:  A Mahgoub; J R Idle; L G Dring; R Lancaster; R L Smith
Journal:  Lancet       Date:  1977-09-17       Impact factor: 79.321

View more
  10 in total

1.  Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients.

Authors:  D Larrey; G Babany; M Tinel; E Freneaux; G Amouyal; F Habersetzer; P Letteron; D Pessayre
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

2.  Is the activation of aflatoxin B1 catalysed by the same form of cytochrome P-450 as that 4-hydroxylating debrisoquine in rat and/or man?

Authors:  S Plummer; A R Boobis; D S Davies
Journal:  Arch Toxicol       Date:  1986-02       Impact factor: 5.153

Review 3.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 4.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 5.  Oxidation phenotype and the metabolism and action of beta-blockers.

Authors:  M S Lennard
Journal:  Klin Wochenschr       Date:  1985-04-01

6.  Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine?

Authors:  G C Kahn; A R Boobis; M J Brodie; E L Toverud; S Murray; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

Review 7.  Genetically determined variability in acetylation and oxidation. Therapeutic implications.

Authors:  D W Clark
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

8.  Attempts to phenotype human liver samples in vitro for debrisoquine 4-hydroxylase activity.

Authors:  A R Boobis; C E Hampden; S Murray; P Beaune; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

9.  Impaired oxidation of debrisoquine in patients with perhexiline liver injury.

Authors:  M Y Morgan; R Reshef; R R Shah; N S Oates; R L Smith; S Sherlock
Journal:  Gut       Date:  1984-10       Impact factor: 23.059

Review 10.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Authors:  Ulrich M Zanger; Sebastian Raimundo; Michel Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-15       Impact factor: 3.000

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.